Virani Shohaib, Akers Austin, Stephenson Kristen, Smith Steven, Kennedy Lindsey, Alpini Gianfranco, Francis Heather
Department of Medical Physiology, College of Medicine Texas A&M Health Science Center, Temple, Texas, USA.
Department of Internal Medicine, Baylor Scott & White Health, Texas, USA.
J Liver. 2018;7(3). doi: 10.4172/2167-0889.1000231. Epub 2018 Sep 20.
Cholestatic liver injury is characterized by damage induced on the biliary tree and cholangiocytes, the cells lining the biliary tree, thus they are termed "cholangiopathies". Cholangiopathies include diseases such as Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Biliary Atresia and Cholangiocarcinoma. These pathologies lack viable therapies and most patients are diagnosed during late stage disease progression (with the exception of Biliary Atresia, which is found shortly after birth). The lack of therapies for these diseases has put a significant burden on the need for liver transplantation as this is the only indicative "cure" for cholangiopathies. The molecular mechanisms for cholangiopathies have been extensively studied; however, and unfortunately, the lack of effective biomarkers and therapeutics remains. In this review article we highlight the latest studies to investigate the molecular mechanisms regulating cholangiopathies and the potential therapeutics that might be discovered.
胆汁淤积性肝损伤的特征是对胆管树及胆管细胞(即衬于胆管树的细胞)造成损伤,因此它们被称为“胆管病”。胆管病包括原发性胆汁性胆管炎、原发性硬化性胆管炎、胆道闭锁和胆管癌等疾病。这些病症缺乏有效的治疗方法,大多数患者在疾病进展晚期才被诊断出来(胆道闭锁除外,它在出生后不久即可发现)。这些疾病缺乏治疗方法给肝移植需求带来了沉重负担,因为这是胆管病唯一具有指征性的“治愈”方法。胆管病的分子机制已得到广泛研究;然而,不幸的是,仍然缺乏有效的生物标志物和治疗方法。在这篇综述文章中,我们重点介绍了调查调节胆管病的分子机制以及可能发现的潜在治疗方法的最新研究。